Withdrawals due to adverse events · men with sexual dysfunction
It is very uncertain whether testosterone changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
2 findings from 1 review
Withdrawals due to adverse events · men with sexual dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · men with sexual dysfunction
Testosterone as an add‐on to PDE5I showed no clear difference in treatment withdrawal due to adverse events compared with PDE5I alone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with drug‐resistant epilepsy
1 finding from 1 review
Withdrawals due to adverse events
It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease
Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review